Cell growth and proliferation are tightly coupled to metabolism, and dissecting the signaling molecules which link these processes is an important step toward understanding development, regeneration, and cancer. The transcriptional regulator Yes-associated protein 1 (YAP) is a key regulator of liver size, development, and function. We now show that YAP can also suppress gluconeogenic gene expression. Yap deletion in primary hepatocytes potentiates the gluconeogenic gene response to glucagon and dexamethasone, whereas constitutively active YAP suppresses it. The effects of YAP are mediated by the transcriptional coactivator peroxisome proliferator-activated receptor-gamma coactivator 1. YAP inhibits its ability to bind to and activate transcription from the promoters of its gluconeogenic targets, and the effects of YAP are blunted upon its knockdown. In vivo, constitutively active YAP lowers plasma glucose levels and increases liver size.
Y es-associated protein 1 (YAP) is a key effector of the Hippo signaling pathway, triggering growth in response to a loss of cell-cell contacts.
(1,2) YAP regulates gene expression to coordinate proliferation, differentiation, and apoptosis pathways. (1, 2) In the liver, YAP activation produces hepatomegaly, whereas Yap deletion leads to the development of smaller, dysfunctional livers. (3) YAP is also required for the regenerative response to hepatic injury (4) and frequently activated in pathological growth, such as hepatocellular carcinoma. (1, 2) Growth and proliferation require adenosine triphosphate (ATP), reducing equivalents, and metabolic building blocks. (5) Genes that induce growth appear to rewire metabolic pathways to produce or acquire these necessary substrates. (6) Consistent with this, YAP has recently been shown to drive expression of glutamine synthetase, which supports the biosynthesis of nucleotide building blocks. (7) The liver, due to its central role in maintaining wholebody homeostasis, faces a unique metabolic challenge. In the fasted state, the liver supplies glucose to the brain and other tissues, to prevent the development of severe hypoglycemia and death. This altruistic response of the liver comes at a cost: each molecule of glucose generated by the hepatocyte consumes six ATP equivalents, two nicotinamide adenine dinucleotide hydrides, and two molecules of pyruvate. We would thus expect gluconeogenesis to be tightly regulated in the proliferating hepatocyte, allowing it to balance the needs of the whole organism for glucose with its own needs for anabolic substrates.
At the hormonal level, gluconeogenesis is activated by several factors, including glucagon. Glucagon acts Abbreviations: AAV, adeno-associated virus; Ad, adenovirus; Alb, albumin; ATP, adenosine triphosphate; Br, Bromo; ChIP, chromatin immunoprecipitation; G6PC, glucose-6-phosphatase catalytic subunit; GFP, green fluorescent protein; HNF4a, hepatocyte nuclear factor 4 alpha; IgG, immunoglobulin G; PCK1, phosphoenolpyruvate carboxykinase 1; PGC1a, peroxisome proliferator-activated receptor gamma coactivator 1; PKA, protein kinase A; rtTA, reverse tetracycline transactivator; sh, short hairpin; TBG, thyroxine-binding globulin; TetO, tetracycline On; YAP, yes-associated protein 1. by binding its receptor, a G protein-coupled receptor, to activate adenylate cyclase and increase cAMP levels, which in turn activate protein kinase A (PKA). This ultimately activates a transcriptional network involving numerous transcription factors and coactivators, including peroxisome proliferator-activated receptorgamma coactivator 1 (PPARGC1a, or PGC1a), to induce the gluconeogenic genes.
Interestingly, YAP is inhibited by glucagon. (8, 9) Glucagon, through PKA, activates the large tumor suppressor homolog 1/2, (8) a core component of the Hippo signaling pathway. Large tumor suppressor homolog 1/2 phosphorylates YAP on S127, which promotes the retention of YAP in the cytoplasm, where it is unable to regulate transcription. (10) (11) (12) We show here that YAP also suppresses expression of the gluconeogenic genes, at least in part by suppressing the transcriptional coactivator PGC1a. This is associated in vivo with decreased plasma glucose levels and suggests that YAP shunts substrates away from the energy-consuming processes of gluconeogenesis and toward anabolic pathways.
Materials and Methods
Please also see the Supporting Information.
ANIMALS AND TREATMENTS
All mice were male, fed a standard chow diet, maintained on a 12-hour light/dark cycle with free access to food and water unless otherwise indicated, and sacrificed at 2:00 PM in the nonfasted state. All animal experiments were performed with the approval of the Institutional Animal Care and Research Advisory Committee at Children's Hospital Boston.
YAP
flox/flox mice and reverse tetracycline transactivator (rtTA) flox/flox ::tetracycline On (TetO)-YAP mice have been described. (13, 14) To knock out YAP, 5-week-old to 7-week-old YAP flox/flox mice were injected with adenoassociated viral vectors (AAV; purchased from the University of Pennsylvania Vector Core) expressing Cre recombinase (AAV8-thyroxine-binding globulin [TBG] Cre, or AAV-Cre) or green fluorescent protein (AAV8-TBG GFP, or AAV-GFP) under the control of a liverspecific TBG promoter. AAVs were administered by retro-orbital injection at a dose of 1.5 3 10 11 genome copies per mouse. Two weeks after AAV injection, mice were subjected to an intraperitoneal glucose tolerance test as described. (15) Mice were fasted for 16 hours and then given 1 g/glucose/kg body weight intraperitoneally at time zero; blood glucose levels were measured using a glucometer. Five weeks after AAV injection, mice were sacrificed. To induce expression of YAP S127A, rtTA flox/flox ::TetO-YAP mice were crossed with mice expressing Cre driven by an albumin (Alb) promoter, yielding Alb-Cre::rtTA flox/flox ::TetO-YAP mice. At 7-9 weeks of age, the drinking water was supplemented or not with doxycycline (1 mg/mL) and administered ad libitum for the remainder of the experiment. Mice were subjected to an intraperitoneal glucose tolerance test 6 days after beginning doxycycline supplementation and sacrificed 9 days after beginning doxycycline supplementation.
PRIMARY HEPATOCYTE STUDIES
Primary hepatocytes were isolated from male YAP flox/flox or Alb-Cre::rtTA flox/flox ::TetO-YAP mice at 8-12 weeks of age, as described. (15) After plating the cells, YAP S127A was induced in primary hepatocytes from Alb-Cre::rtTA flox/flox ::TetO-YAP mice by treating with 100 ng/mL doxycycline overnight.
ARTICLE INFORMATION:
For adenovirally mediated overexpression, adenoviruses were added to cell culture media at multiplicities of infection of 10 to 50 for 24 hours prior to harvest. Alternatively, for adenovirally mediated knockdown of PGC1a, hepatocytes were incubated with adenovirus (Ad)-short hairpin (sh) PGC1a or Ad-shLamin for 48 hours prior to harvest, and treated with Ad-GFP or Ad-YAP S127A for 24 hours prior to harvest. Adenovirus expressing YAP S127A (Ad-YAP S127A) has been described (16) ; adenoviruses expressing PGC1a (Ad-PGC1a), LacZ (AdLacZ), and an shRNA against PGC1a (Ad-shPGC1a) were gifts from Dr. Pere Puigserver (Dana Faber Cancer Institute) (17) ; adenovirus against human lamin (AdshLamin), used as a control, has been described. (15) Adenoviruses expressing GFP (Ad-GFP) and Cre (AdCre) were purchased from ViraQuest. All viruses were amplified in 293A cells per the manufacturer's instructions.
The day of harvest the medium was replaced with fresh Williams' E medium supplemented with 2 mM glutamine, 100 units/mL penicillin, 100 units/mL streptomycin, and 10% fetal bovine serum (without doxycycline or adenovirus). Cells were treated with or without 10 nM glucagon (Sigma) for 1.5 hours, 1 mM 8-Bromo (8-Br)-cAMP (Sigma) for 1.5 hours, 10 mM forskolin (Sigma) for 1.5 hours, or 200 nM dexamethasone (Sigma) for 6 hours. All cells were harvested at the same time, at the conclusion of the experiment.
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) assays using primary hepatocytes and liver tissues were performed as described with minor modifications. (18, 19) The immunoprecipitated DNA as well as 10% of the precleared chromatin (input DNA) were subjected to real-time PCR using Power SYBR Green PCR Master Mix (Life Technologies), in triplicate. For each immunoprecipitate, we calculated the relative enrichment as 2 2DCt , where DCt was calculated as the average value obtained from the immunoprecipitate DNA minus the average value obtained from the input DNA. The relative enrichment of replicate immunoprecipitates (two to four per group) was averaged, and the results were expressed in arbitrary units, with the immunoglobulin G (IgG) control for each primer pair set to 1. Representative results of two to four independent experiments are shown. The antibodies used in the ChIP assays are listed in Supporting Table S2 , and real-time PCR primers are listed in Supporting Table S3 .
MICROARRAY STUDIES

Generation of the YAP Target Gene Set
To identify hepatic YAP targets in an unbiased manner, we analyzed microarray data obtained from the livers of control mice and mice expressing YAP S127A in their livers for 1 or 6 weeks (Gene Expression Omnibus accession GSE55559 (2) ). For each probe set, expression at each time point was compared to expression in the control using moderated t tests from the limma package (9) ; P values from both time points were then combined using the z.transform method in the combine.test function of the survcomp package. (10) The eight most significant probesets that were associated with a gene symbol and upregulated at both time points were defined as the "YAP target gene set" (see also Supporting Information).
Gene Set Enrichment Analysis
Microarray data from liver samples obtained from patients with hepatocellular carcinoma were retrieved (GSE64041 (20) ). We removed the unpaired normal samples and used the paired biopsies of tumor and surrounding nontumor regions from the livers of 60 patients with hepatocellular carcinoma. We calculated log 2 ratios of the expression in the tumor versus the surrounding nontumor region for each probe set. To determine whether the YAP target gene set (generated as described above) was significantly up-regulated and the gluconeogenic genes (based on the gluconeogenic gene set defined in HumanCyc (21) ) were significantly altered in the tumors, we used the fry function implementing the ROAST method in the limma package, which can exploit the paired nature of the data set. (22) We examined the P value of the gluconeogenic gene set using the mixed (nondirectional) test, whereas we confirmed that the YAP target gene set was significantly up-regulated.
Correlation Analysis
For each patient, we averaged the log 2 ratios of the expression in the tumor versus the surrounding nontumor region for all of the genes in the YAP target gene set as well as all of the genes in the gluconeogenic gene set and plotted them against one another; the correlation coefficients and their P values were calculated using the cor.test function. All bioinformatics analyses were done in the R software (23) and are available upon request.
STATISTICAL ANALYSIS
In Vitro Studies
Gene expression studies were performed with triplicate wells. Bars and error bars correspond to the mean and SEM, respectively. Representative results of two to five independent experiments are shown. Differences between groups were assessed by a two-tailed unequal variance Student t test.
Mouse Studies
Animals were randomized to control and experimental groups. Bars and error bars correspond to the mean and SEM, respectively. Representative results of two to four independent experiments are shown. Differences between groups were assessed by a two-tailed unequal variance Student t test.
Results
YAP SUPPRESSES INDUCTION OF GLUCONEOGENIC ENZYMES
To determine how YAP affects the gluconeogenic gene response, we studied primary hepatocytes with either constitutively active YAP or knockdown of YAP. For constitutive activation of YAP, a mutant form of YAP, resistant to phosphorylation on serine 127 (YAP S127A), was expressed under a doxycycline-inducible promoter. These hepatocytes were isolated from the livers of Alb-Cre::rtTA flox/flox ::TetO-YAP mice, which harbor a transgene encoding a mutant form of human YAP, in which serine 127 is mutated to alanine, under the control of the TetO promoter (14) : Cre recombinase, under the Alb promoter, drives rtTA; rtTA, in the presence of doxycycline, drives YAP S127A (Supporting Fig. S1A ). Thus, doxycycline treatment of these hepatocytes increased total YAP levels (Fig. 1A) .
In control cells, glucagon induced the gluconeogenic genes glucose-6-phosphatase catalytic subunit (G6pc) and phosphoenolpyruvate carboxykinase 1 (Pck1) more than 500-fold (Fig. 1B) . In cells treated with doxycycline to induce YAP S127A, however, the effects of glucagon were almost entirely abolished (Fig. 1B) . Consequently, YAP S127A suppressed G6pc and Pck1 more than 99% in the presence of glucagon. In parallel, YAP S127A blunted the ability of the cAMP analogue 8-Br-cAMP and the activator of PKA forskolin to induce the gluconeogenic genes (Fig. 1C,D) .
Glucocorticoids also induce expression of G6pc and Pck1. Thus, treatment of hepatocytes with dexamethasone, a synthetic glucocorticoid that activates the glucocorticoid receptor, also strongly induced the gluconeogenic genes. Interestingly, YAP S127A was able to almost abolish the induction of the gluconeogenic genes in response to dexamethasone, and YAP S127A reduced G6pc and Pck1 by 80%-90% in dexamethasone-treated cells (Fig. 1E) . Similar effects of YAP S127A on the gluconeogenic gene response to glucagon, forskolin, and dexamethasone were obtained using an adenovirus encoding YAP S127A, rather than the doxycycline-inducible transgene (Supporting Fig. S1B,C) .
Conversely, we examined the ability of glucagon to activate transcription of G6pc and Pck1 in hepatocytes with knockdown of YAP. In this case, cells from Yap flox/flox mice were treated in vitro with adenovirus encoding either GFP or Cre recombinase. Knockdown of YAP was confirmed by reduced YAP protein and mRNA levels after Ad-Cre infection ( Fig. 2A) . We found that glucagon stimulation of G6pc and Pck1 was significantly potentiated by the knockdown of YAP. Thus, in cells treated with glucagon (Fig. 2B ), 8-Br-cAMP (Fig. 2C), forskolin (Fig.  2D ), or dexamethasone (Fig. 2E) , YAP deletion increased expression of G6pc and Pck1 by 25%-300%.
YAP SUPPRESSES Pck1 AND G6pc THROUGH PGC1a
PGC1a is a powerful activator of the gluconeogenic genes and is induced by glucagon. Thus, glucagon increased Pgc1a mRNA levels 10-fold to 20-fold in control hepatocytes. This effect was abolished by YAP S127A and potentiated by YAP knockdown (Fig. 3A) . Taken together, these results indicate that YAP can suppress Pgc1a in the presence of glucagon.
To determine whether constitutive expression of PGC1a could overcome the effects of YAP S127A on the gluconeogenic genes, we treated cells with adenovirus encoding either Pgc1a or LacZ. Adenoviral treatment markedly increased Pgc1a mRNA levels (Fig. 3B) , as well as protein levels (Supporting Fig. S2A) . Interestingly, the ability of PGC1a to activate expression of the gluconeogenic genes was blunted by YAP S127A (Fig. 3B) . Thus, YAP S127A impaired the ability of PGC1a to activate the gluconeogenic genes even when Pgc1a mRNA levels were not different (Fig. 3B) .
PGC1a is also known to activate transcription of the genes involved in oxidative phosphorylation (including Cycs and Cox5b), the tricarboxylic acid cycle (including Idh3a), and fatty acid oxidation (including Vlcad). (24) Consistent with this, PGC1a overexpression increased these targets by 3-fold to 10-fold in control cells (Fig.  3B) . Interestingly, YAP S127A had no effect on the ability of PGC1a to induce Cycs and reduced the other nongluconeogenic targets of PGC1a by only 10%-20%. Thus, YAP S127A appeared to preferentially impair PGC1a's activation of its gluconeogenic targets.
Conversely, deletion of YAP preferentially potentiated PGC1a activation of its gluconeogenic targets. Thus, PGC1a increased expression of G6pc and Pck1 by 2-fold to 4-fold in control cells but 6-fold to 10-fold in hepatocytes with knockout of YAP (Fig. 3C) . On the other hand, with the exception of ldh3a, the deletion of YAP did not significantly alter on the nongluconeogenic targets of PGC1a (Fig. 3C) . PGC1a induces expression of the gluconeogenic genes by coactivating numerous transcription factors, including hepatic nuclear factor 4 alpha (HNF4a). YAP did not alter levels of HNF4a (Supporting Fig.  S2B ) but did appear to reduce the ability of PGC1a to coactivate HNF4a on the PCK1 promoter: luciferase reporters in HepG2 cells showed that PGC1a in combination with HNF4a was able to stimulate PCK1 transcription by 3-fold but that this was reduced 50% by YAP S127A (Fig. 3D) . Similarly, PGC1a in combination with glucocorticoid receptor, which is also coactivated by PGC1a, and dexamethasone was able to induce PCK1 transcription 6-fold; but this was again reduced 50% by YAP S127A (Fig. 3D) .
To further examine the effects of YAP on the ability of PGC1a to activate transcription, we performed ChIP assays using control antibodies (IgG) or antibodies against PGC1a. Thus, primary hepatocytes from Alb-Cre::rtTA flox/flox ::TetO-YAP were infected with adenovirus encoding PGC1a or LacZ and treated with or without doxycycline to induce YAP S127A. PGC1a was associated with regions within the G6pc (-310 to -231 and -215 to -111) and Pck1 (-700 to -599 and -615 to -517) promoters but not regions outside of the promoter (Pck1, -3678 to -3564). The association of PGC1a with the G6pc promoter, as well as the Pck1 promoter, was reduced 75% in the presence of YAP S127A (Fig. 3E) . Conversely, the association of PGC1a with the G6pc and Pck1 promoters was slightly enhanced by knockdown of Yap (Supporting Fig. S2D ). Importantly, YAP appeared to alter the ability of PGC1a to bind to the promoters of the gluconeogenic genes without altering PGC1a protein levels (Supporting Fig. S2C,E) .
Finally, to determine the extent to which PGC1a was required for the effects of YAP S127A, we knocked down Pgc1a in forskolin-treated cells. Thus, control hepatocytes were treated with adenovirus encoding an shRNA against Pgc1a; a control shRNA, YAP S127A; and/or GFP. In control cells, YAP S127A suppressed G6pc and Pck1 13-fold and 8-fold, respectively. Upon knockdown of Pgc1a, YAP S127A suppressed G6pc and Pck1 by only 4-fold and 2-fold, respectively (Fig. 3F ).
OVEREXPRESSION OF YAP IS SUFFICIENT TO SUPPRESS HEPATIC GLUCONEOGENIC GENE EXPRESSION AND LOWER PLASMA GLUCOSE LEVELS IN VIVO
To determine the effects of YAP deletion in vivo, YAP flox/flox mice were infected with AAV expressing Cre recombinase or GFP under the control of a liver-specific TBG promoter: AAV8-TBG Cre (or AAV-Cre) or AAV8-TBG GFP (or AAV-GFP) and sacrificed 5 weeks later. Despite the fact that AAV-Cre reduced Yap mRNA levels by 85% (Supporting Fig. S3A ), no changes were observed in body weight (Supporting Fig. S3B ), liver weight (Supporting Fig. S3C ), or expression of the YAP targets Ctgf and Cyr61 (Supporting Fig. S3D) . Moreover, knockdown of Yap had no significant effect on gluconeogenic gene expression, glucose levels, or glucose tolerance (Supporting Fig. S3E-G) . These data indicate that YAP has little contribution to glucose homeostasis in the normal adult liver.
To determine the effects of constitutively active YAP in vivo, Alb-Cre::rtTA flox/flox ::TetO-YAP mice were administered water with or without doxycycline supplementation for 9 days prior to sacrifice. YAP S127A did not alter the body weights of the mice (Fig. 4A ) but increased expression of Ctgf and Cyr61 (Supporting Fig. S4A ) and doubled the weight of the liver ( Fig. 4B; Supporting Fig. S4B) . Interestingly, mRNA levels of hepatic G6pc and Pck1, but not the fatty acid oxidation or mitochondrial genes, were decreased 75%-90% in doxycycline-treated mice (Fig. 4C) . PGC1a trended lower at both the mRNA and protein levels ( Fig. 4C; Supporting Fig. S4D ), but no changes were noted in HNF4a or cAMP responsive element-binding protein (Supporting Fig. S3C,D) . Nonetheless, ChIP assays showed that binding of PGC1a to G6pc and Pck1 promoters was markedly decreased in the presence of YAP S127A (Fig. 4G) . These data suggest that in vivo, as in vitro, YAP S127A was sufficient to suppress gluconeogenic gene expression. Consistent with this, the induction of YAP S127A decreased random fed blood glucose levels (Fig. 4D ) and improved glucose tolerance (Fig. 4E,F) .
YAP ACTIVATION IS ASSOCIATED WITH SUPPRESSION OF GLUCONEOGENIC GENES IN HEPATOCELLULAR CARCINOMA
Because YAP is frequently induced in human hepatocellular carcinomas, we examined the relationship between YAP activity and gluconeogenic gene expression using liver microarray data obtained from paired biopsies taken from tumor and surrounding nontumor regions in 60 patients with hepatocellular carcinoma. (20) To assess YAP activation, we generated, in an unbiased manner, a set of genes (referred to as the "YAP target gene set") induced by YAP S127A expression in the livers of mice. (14) Gene set enrichment analysis revealed that the YAP target gene set was significantly induced in the tumors compared to the surrounding nontumor regions (P 5 4 3 10
27
; false discovery rate 5 8 3 10
), consistent with YAP activation in the tumors. We then plotted the average change in expression of the YAP target genes against the average change in expression of the gluconeogenic genes for each patient (Fig. 5A ). We found a strong inverse correlation between YAP activation and gluconeogenic gene expression (r 5 -0.57, p 5 2.3 3 10
26
). Similar strong, inverse correlations were found between G6PC and PCK1 expression and the canonical YAP targets CTGF, BIRC5, and SPP1 (Supporting Fig. S5A-F) .
To determine whether the suppression of PGC1a might be important for the growth-promoting effects of YAP, we infected Hepa1c1c7 cells with adenoviruses encoding GFP, YAP S127A, and/or PGC1a and measured cell mass at several time points afterward, using a sulforhodamine B assay. (7) We found that Ad-YAPS127A increased cell mass, as expected, but that Ad-PGC1a, either alone or in combination with Ad-YAPS127A, lowered cell mass (Fig. 5B) . Thus, suppression of PGC1a appears to be required for the growth-promoting effects of YAP.
Discussion
Here, we show that YAP effectively suppresses the gluconeogenic response to glucagon in a PGC1a-dependent manner. Thus, the ability of glucagon, as well as dexamethasone, to induce expression of the gluconeogenic genes Pck1 and G6pc is almost abolished in the presence of YAP S127A. Conversely, inactivation of YAP leads to a derepression of these genes. The effect of YAP on G6pc and Pck1 is mediated in large part by PGC1a as the effects of YAP are blunted by FIG. 4 . YAP suppresses hepatic gluconeogenic gene expression in vivo. Alb-Cre::rtTA flox/flox ::TetO-YAP mice, 7-9 weeks old, were sacrificed after being treated with doxycycline for nine days to induce YAP S127A (1 DOX) or left untreated (controls, 2DOX). Body weight (A), liver to body weight ratio (B), and blood glucose levels (D) were measured at the time of sacrifice. Gene expression (C) was measured by real-time RT-PCR. A glucose tolerance test was performed after 6 days of doxycycline treatment (E), and the glucose area under the curve was calculated (F). Data are presented as the mean and SEM (n 5 4-7). Statistical significance was assessed by Student t test; *P < 0.05 versus mice not administered doxycycline. (G) ChIP assays were performed using an antibody against PGC1a or control IgG. Relative enrichment of PGC1a was assessed by real-time PCR using primers against the indicated regions of the G6pc and Pck1 genes. Data are presented as the mean and SEM (n 5 3 technical replicates per condition). Statistical significance was assessed by Student t test; *P < 0.05 versus without doxycycline treatment and # P < 0.05 versus control IgG. Abbreviations: AUC, area under the curve; Dox, doxycycline; IP, immunoprecipitation. knockdown of PGC1a. Mice expressing YAP S127A in their livers show reduced expression of the gluconeogenic genes and lower levels of plasma glucose.
Several pieces of data point to PGC1a as a key mediator of YAP's effects on the gluconeogenic genes. First, the effects of YAP on the gluconeogenic genes are observed only under conditions in which PGC1a is induced: glucagon stimulation, dexamethasone stimulation, and PGC1a overexpression (Figs. 1B-E, 2B-E, and 3B,C). In contrast, no effects of YAP are observed in the basal state. Second, PGC1a is sufficient to confer sensitivity of the gluconeogenic genes to YAP (Fig.  3B,C) . Third, YAP reduces the accumulation of PGC1a on the promoters of the gluconeogenic genes (Figs. 3E and 4G) . And, finally, the effects of YAP are largely, but not entirely, diminished after knockdown of PGC1a (Fig. 3F) . The residual ability of YAP to suppress the gluconeogenic genes after PGC1a knockdown may be due to additional PGC1a-independent effects of YAP on these genes.
Importantly, YAP appears to preferentially impair the ability of PGC1a to activate its gluconeogenic targets (Fig. 3B,C) . Thus, YAP almost entirely suppresses gluconeogenic gene expression but only modestly reduces the fatty acid oxidation or mitochondrial gene targets of PGC1a. These data suggest that YAP modulates PGC1a, preventing PGC1a from driving the consumption of ATP by gluconeogenesis, while largely preserving its ability to drive the production of ATP through fatty acid oxidation and oxidative phosphorylation.
Exactly how YAP regulates PGC1a is not yet clear. In contrast to PGC1a, YAP does not appear to be present on the promoters of the gluconeogenic genes (Supporting Figs. S2F and 4E) . Moreover, we were unable to detect PGC1a in immunoprecipitates of YAP (data not shown). Taken together, these data suggest that the effects of YAP on PGC1a may be indirect. Indeed, the literature suggests S6 kinase as one potential indirect mediator: YAP overexpression activates S6 kinase (25) ; S6 kinase phosphorylates PGC1a on its arginine/serine-rich domain (24) ; and PGC1a phosphorylation by S6 kinase selectively inhibits the ability of PGC1a to coactivate its gluconeogenic, but not mitochondrial, gene targets. (24) YAP suppresses Pgc1a mRNA levels under some, but not all, conditions. PGC1a transcription is driven, in part, by a positive feedback loop, in which PGC1a coactivates transcription of its own promoter. (26) Thus, YAP could impair the ability of PGC1a to coactivate the Pgc1a promoter, as it does the G6pc and Pck1 promoters. Consistent with this, YAP suppressed endogenous Pgc1a mRNA in the presence of glucagon (Fig.   FIG. 5. (A) Gene expression in paired biopsies of tumor and nontumor regions obtained from the livers of patients with hepatocellular carcinoma (n 5 60). (20) The average log ratio of the gluconeogenic genes (y axis) was plotted against the average log ratio of the YAP target genes (x axis), with each point representing data from a single patient. (B) Proliferation of mouse hepatoma cells over 5 days in the presence of adenoviruses expressing GFP, YAP S127A, and/or PGC1a. Data are presented as the mean and SEM (n 5 4). Statistical significance was assessed by Student t test; *P < 0.05 versus Ad-GFP-treated and # P < 0.05 versus treatment with both Ad-YAP S127A and Ad-PGC1a. 3A) but did not suppress exogenous Pgc1a mRNA, driven by the cytomegalovirus promoter (Fig. 3B) .
Our data also show that YAP must be inactivated for the full gluconeogenic gene response to glucagon. Regulation of the gluconeogenic response is highly complex, involving multiple transcription factors and coactivators. The canonical pathway by which glucagon activates gluconeogenesis is the cAMP/PKA signaling pathway, which ultimately leads to the activation of cAMP responsive element-binding protein and its regulated transcription coactivator 2, in addition to PGC1a. Our data reveal the existence of yet another layer of regulation, in which PKA signaling also inhibits YAP, permitting PGC1a activation of the gluconeogenic targets.
In the hepatocytes of normal adult livers, YAP expression is very low, (14) which most likely renders the deactivation of YAP by glucagon superfluous. Consistent with this, knockout of YAP in the livers of adult mice had little effect on either gluconeogenic gene expression or plasma glucose levels (Supporting Fig. S3 ). However, in the postnatal developing liver and the regenerating liver, YAP is present. (3) Under these conditions, glucagon regulation of YAP may become important in balancing the hepatocyte's need to meet the anabolic demands of growth with the opposing needs of the organism to prevent hypoglycemia. For example, in the perinatal period, the organism is highly susceptible to hypoglycemia and glucagon plays an important role in maintaining blood glucose levels by driving gluconeogenesis. (27) During this critical period, the ability of glucagon to override YAP inhibition of PGC1a and gluconeogenesis may be necessary for the maximal response to gluconeogenesis. It is also interesting to note that two other hormones involved in the hypoglycemic response, epinephrine and insulin, could act in parallel with glucagon to suppress YAP: epinephrine, which also acts through a G protein-coupled receptor to inhibit YAP, (9) is increased with hypoglycemia, whereas insulin, which may activate YAP, (28) is decreased with hypoglycemia. YAP is also activated in many forms of liver cancer. Our data show that activation of YAP targets is correlated with suppression of gluconeogenic genes in the liver. YAP suppression of the gluconeogenic genes could explain data accumulated over the last five decades showing that gluconeogenesis is inhibited in tumor cells. (29) (30) (31) (32) It could also potentially explain, in part, the hypoglycemia associated with some forms of liver cancer. (33, 34) The ability of YAP to suppress gluconeogenesis may very well play an important part in its ability to drive tumorigenesis (Fig. 5A) . Indeed, patients with mutations in G6pc are prone to the development hepatic adenomas, (29) and therapies designed to induce gluconeogenesis appear to be beneficial in the treatment of hepatic carcinoma. (35, 36) In summary, our data identify PGC1a and the gluconeogenic genes as important targets of YAP in the liver. By preventing the diversion of ATP, reducing equivalents and building blocks to gluconeogenesis, YAP, a master regulator of growth and proliferation, appears to rewire cellular metabolism to support the anabolic demands of growth.
